IOM prioritizes OTC contraceptive, supplement research
This article was originally published in The Tan Sheet
An Institute of Medicine 1report to Congress on priority topics for comparative effectiveness research lists research on "innovative strategies for preventing unintended pregnancies" - including OTC access to oral contraceptives and other hormonal methods - as a top-tier priority. Lower-level items in the inventory of 100 priorities include comparing the effectiveness of dietary supplements in treating prevalent conditions, smoking-cessation strategies in minority and adolescent populations, and consumer self-care in avoiding early morbidity among people with mental illness. IOM submitted the report June 30 as required by the American Recovery and Reinvestment Act of 2009. The law charged IOM with recommending projects the Department of Health and Human Services should fund with the $1.1 billion allocated for CER (2"The Tan Sheet" March 16, 2009)
You may also be interested in...
Senate Finance Committee Chairman Max Baucus continues planning to include comparative effectiveness in the health care reform debate, even with research funding included in the American Recovery and Reinvestment Act
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.